Resources Repository
-
ArticlePublication 2018Equity Impact Vaccines May Have on Averting Deaths and Medical Impoverishment
In this analysis, authors estimated the number of deaths averted and the number of cases …
In this analysis, authors estimated the number of deaths averted and the number of cases of medical impoverishment averted of ten antigens and their corresponding vaccines across income quintiles for forty-one low- and middle-income countries. The study found that vaccines administered between 2016 and 2030 would prevent 36 million deaths. Vaccines will have the greatest impact on reducing cases of poverty caused by hepatitis B, helping an estimated 14 million people avoid medical impoverishment. An…
Mathematical Models | Costing Methods | Health/Medicine | Economics/Finance | Child/Nutrition | Infectious Diseases | Priority Setting/Ethics | Health Outcomes | Cost-Effectiveness Analysis | Global Governance | Science/Technology | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific -
ArticlePublication 2017Getting it Right When Budgets are Tight: Prioritizing Responses to HIV Epidemics
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and …
Prioritizing investments across health interventions is complicated by the nonlinear relationship between intervention coverage and epidemiological outcomes. It can be difficult for countries to know which interventions to prioritize for greatest epidemiological impact, particularly when budgets are uncertain.The authors examined four case studies of HIV epidemics in diverse settings, each with different characteristics. These case studies were based on public data available for Belarus, Peru, Togo, and Myanmar. The Optima HIV model and software package…
Mathematical Models | Costing Methods | Health/Medicine | Economics/Finance | Health Systems | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2016Funding Gap for Immunization Across 94 Low- and Middle-Income Countries
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 …
This analysis estimates immunization program costs, potentially available financing, and resulting funding gap for 94 low- and middle-income countries over the five-year period of 2016–2020. Vaccine financing by country governments, GAVI, and other development sources was forecasted for vaccine, supply chain, and service delivery based on an analysis of comprehensive multi-year plans together with a series of scenarios. The authors found that that delivery of full vaccination programs across the 94 countries would result in a total…
Mathematical Models | Costing Methods | Health/Medicine | Economics/Finance | Health Systems | Infectious Diseases | Cost-Effectiveness Analysis | Global Governance | Sub-Saharan Africa | Middle East & North Africa | Latin America & Caribbean | Asia & Pacific -
ArticlePublication 2008Mathematical Models of Cervical Cancer Prevention in the Asia Pacific Region
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, …
This article reports on a model-based approach to estimate averted cervical cancer cases and deaths, disability-adjusted life years (DALYs) and incremental cost-effectiveness ratios (I$/DALY averted) for vaccination of young adolescent girls against human papillomavirus (HPV) types 16 and 18. The authors used population-based and epidemiologic data for 25 countries in Asia (22 GAVI-Alliance eligible countries, Thailand, China and Japan). They found that an absolute reduction in lifetime cancer risk varied across countries, depending on incidence,…
Mathematical Models | Calibration/Validation | Health/Medicine | Economics/Finance | Health Systems | Infectious Diseases | Microsimulation | Cost-Effectiveness Analysis | Chronic Disease/Risk | Science/Technology | Asia & Pacific -
ArticlePublication 2007Economic Evaluation of Hepatitis B Vaccination in Low-Income Countries: Cost-Effectiveness Affordability Curves
In the face of uncertainties about both the health and economic consequences of a vaccine …
In the face of uncertainties about both the health and economic consequences of a vaccine program, as well as the availability and magnitude of resources needed to fund the program, cost-effectiveness affordability curves can provide information to decision-makers about the probability that a program will be both cost-effective and affordable: these are distinct but equally relevant considerations in resource-poor settings. This paper describes the application of this method to assess a hepatitis B vaccination program in the…
Mathematical Models | Costing Methods | Health/Medicine | Economics/Finance | Health Systems | Infectious Diseases | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Sub-Saharan Africa -
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Costing Methods | Health/Medicine | Economics/Finance | Health Systems | Child/Nutrition | Infectious Diseases | Health Outcomes | Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Social Determinants | Policy/Regulation | Global Governance | Government/Law | Science/Technology | Global -
ArticlePublication 2017Cost Determinants of Routine Infant Immunization Services
The EPIC study collected data on routine infant immunization costs from Benin, Ghana, Honduras, Moldova, …
The EPIC study collected data on routine infant immunization costs from Benin, Ghana, Honduras, Moldova, Uganda, Zambia, using a standardized approach. The authors estimated how costs were distributed across budget categories and programmatic activities, and investigated how the cost structure of immunization sites varied by country and site characteristics. For each country, the economic costs of infant immunization were estimated by administrative level, budget category, and programmatic activity from a program perspective. Regression models were…
Costing Methods | Health/Medicine | Economics/Finance | Health Systems | Child/Nutrition | Infectious Diseases | Sub-Saharan Africa | Latin America & Caribbean -
Resource PackPublication, Teaching Resource 2017Resource Pack: Disease Control Priorities
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced …
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced by the Disease Control Priorities 3 (DCP3) to inform program design and resource allocation at the global and country levels. Analyses focus on the effectiveness, cost, and cost-effectiveness of priority interventions. Learn more by visiting the DCP3 website.
Costing Methods | Health/Medicine | Economics/Finance | Health Systems | Child/Nutrition | Infectious Diseases | Evidence Synthesis | Benefit-Cost Analysis | Cost-Effectiveness Analysis | Maternal/Reproductive Health | Chronic Disease/Risk | Mental Health | Injuries/Accidents | Global | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2016Cost-Effectiveness of Routine Vaccination With a Live-Attenuated Dengue Vaccine: Model Comparison
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, …
Large Phase III trials across Asia and Latin America have demonstrated the efficacy of a recombinant, live-attenuated dengue vaccine (Dengvaxia) over the first 25 months following vaccination. Subsequent data collected in the longer-term follow-up phase, however, have raised concerns about a potential increase in hospitalization risk of subsequent dengue infections, in particular among young, dengue-naïve vaccinees. This paper reports predictions from eight independent modelling groups on the long-term safety, public health impact, and cost-effectiveness of routine…
Mathematical Models | Health/Medicine | Economics/Finance | Health Systems | Child/Nutrition | Infectious Diseases | Dynamic Transmission | Cost-Effectiveness Analysis | Global Governance | Climate/Environment | Latin America & Caribbean | Asia & Pacific